ENFN250117C5000
- 0.00
- 0.000.00%
Enfusion Newsroom
Enfusion Is Maintained at Neutral by Piper Sandler
Piper Sandler Maintains Enfusion(ENFN.US) With Hold Rating, Raises Target Price to $11.5
Enfusion (ENFN) Receives a Hold From Piper Sandler
12 Information Technology Stocks Moving In Thursday's Pre-Market Session
AI applications are accelerating penetration, and the stocks of Microsoft, ServiceNow, and other software companies continue to rise.
Stifel indicates that Microsoft and some Software companies are expected to continue their growth through AI monetization by 2025.
Stifel Maintains Enfusion(ENFN.US) With Buy Rating, Raises Target Price to $13
Stifel Maintains Buy on Enfusion, Raises Price Target to $13
Enfusion Analyst Ratings
Orbus Software Announces Strategic Growth Investment From FTV Capital and SilverTree Equity
Have Insiders Sold Enfusion Shares Recently?
Enfusion To Present at Upcoming Investor Events
An Intrinsic Calculation For Enfusion, Inc. (NYSE:ENFN) Suggests It's 38% Undervalued
There May Be Some Bright Spots In Enfusion's (NYSE:ENFN) Earnings
Morgan Stanley Maintains Enfusion(ENFN.US) With Buy Rating, Maintains Target Price $11
Enfusion: A Strategic Opportunity With High Growth Potential and Attractive Valuation
Analysts Offer Insights on Technology Companies: Block (SQ), Silicon Laboratories (SLAB) and Enfusion (ENFN)
Stifel Maintains Enfusion(ENFN.US) With Buy Rating, Raises Target Price to $11
Enfusion | 10-Q: Q3 2024 Earnings Report
Enfusion: Strong Client Acquisitions and Strategic Positioning Drive Buy Rating
Enfusion, Inc. (ENFN) Q3 2024 Earnings Call Transcript Summary